CLINICAL NEWS
The U.S. FDA approved brentuximab
vedotin for the post-autologous hematopoietic stem cell transplantation
(auto-HSCT) consolidation treatment of
patients with classical Hodgkin lymphoma at high risk of relapse or progression. The approval was based on the
results of a randomized, double-blind,
placebo-controlled trial that included
329 patients with classical Hodgkin
lymphoma. After auto-HSCT, patients
were randomized 1:1 to receive brentux-
fatigue, peripheral motor neuropathy,
nausea, cough, and diarrhea. The most
commonly reported serious adverse
events included pneumonia, pyrexia,
vomiting, nausea, hepatotoxicity, and
peripheral sensory neuropathy. Of the
patients in the brentuximab vedotin
group, infusion-related reactions were
reported in 15 percent of patients (n=25)
and pulmonary toxicity was reported in
five percent of patients (n=8).
imab vedotin or placebo once every three
weeks for a maximum of 16 cycles. The
median progression-free survival in the
brentuximab vedotin cohort was 42.9
months, compared with 24.1 months in
the control group (hazard ratio=0.57;
95% CI 0.40-0.81; p=0.001). The most
commonly reported treatment-associated
adverse events for the brentuximab vedotin group were neutropenia, peripheral
sensory neuropathy, thrombocytopenia,
anemia, upper respiratory tract infection,
Source: U.S. FDA press release
First Study to Show
T-Cell Therapy Response in Multiple
Myeloma
A new study published in Nature
Medicine indicated that T-cell receptor
therapy using a patient’s own immune
system to recognize and destroy cancer
T:7”
Table 4: All Adverse Reactions in ≥5.0% and Grade 3/4 Adverse Reactions
in ≥ 1.0% of Patients in the Rd Continuous or Rd18 Arms*
All Adverse Reactionsa
Table 4: All Adverse Reactions in ≥5.0% and Grade 3/4 Adverse Reactions
in ≥ 1.0% of Patients in the Rd Continuous or Rd18 Arms*
Grade 3/4 Adverse
Reactionsb
Grade 3/4 Adverse
Reactionsb
All Adverse Reactionsa
Rd
Rd
System organ class Continuous Rd18
MPT Continuous Rd18
MPT
Preferred term
(N = 532) (N = 540) (N = 541) (N = 532) (N = 540) (N = 541)
Rd
Rd
System organ class Continuous Rd18
MPT Continuous Rd18
MPT
Preferred term
(N = 532) (N = 540) (N = 541) (N = 532) (N = 540) (N = 541)